A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...
Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
News-Medical.Net on MSN
PTGES3 emerges as key regulator of androgen receptor in prostate cancer
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback